Patent granted for toxoplasmosis research

  • April 29, 2014
Patent granted for toxoplasmosis research

Bo Shiun Lai and his research colleagues have been granted a patent by the US authorities to develop a treatement for toxoplasmosis.

A Gates Cambridge Scholar and his team have been granted a patent by the US authorities to develop a treatement for toxoplasmosis.

Bo Shiun Lai [2013] and colleagues submitted a patent application around a year and a half ago when Bo Shiun was still doing his undergraduate degree at the Univesity of Chicago and have just been awarded a US patent. He is continuing his research at the University of Cambridge, where he is doing a PhD in Pathology.

Toxoplasmosis is a parasite which is hosted by two billion people worldwide, mostly without any visible symptoms. However, if their immune system is suppressed, for instance, if they are newborn or have HIV, it can cause serious problems. In newborns it can cause ocular impairment or brain defects and brain inflammation caused by toxoplasmosis is a major cause of death in people with HIV. It is relatively rare among newborns and has been considered a neglected disease, but since 9/11, it has been classified as a bioterror agent by the US National Institute of Allergy and Infectious Diseases (NIAID) which led to increased interest until the financial meltdown.

Toxoplasmosis takes two forms: active and dormant. When it is dormant the parasite wraps itself in a thick layer of lipid which makes it impervious to all drug treatment and impossible to eradicate. Bo Shiun’s research into toxoplasmosis focuses on two main challenges: how to deliver drugs across the lipid barrier and what specific molecular pathways to inhibit. As toxoplasmosis mainly resides in the eyes and brain, treatment has to cross the ocular membrane or enter the brain.

His work prior to arriving at Cambridge in 2013 was focused on the first challenge, attempting to create a molecule that could have an inhibitory effect on the parasite and deliver medication across multiple membranes. At Cambridge, he has been targeting the second challenge – how to switch the parasite from dormant to active mode, making it susceptible to existing treatment, or shut off essential pathways, killing the parasite effectively.

He says: “This approach is a breakthrough because it allows us to deliver drugs across numerous layers of obstacles, arrive at the intended target (ideally essential for parasite survival or replication), and abrogate parasite growth. The patent is promising for delivering inhibitory molecules into both active and dormant parasites.”

The researchers found that their original model had a small therapeutic range in which it could be both effective and non toxic. They believe the toxicity originates from the transductive peptides which help deliver the drugs across the lipid barrier to the parasite and have been trying to reduce it. So far they have expanded the therapeutic range by about four times. Bo Shiun says: “This means we can increase the dosage dramatically without observable toxicity.”

Bo Shiun’s work has seen him nominated for the Cozzarelli Prize, a national award for scientific excellence in a particular scientific discipline and three of his articles were accepted for publication in peer review journals before he finished his undergraduate degree.

Latest News

Climate change: the world’s greatest challenge

Three Gates Cambridge alumnae took part in the first of a series of online panels to celebrate the scholarship programme’s 20th anniversary. The panel discussion, Climate change: the world’s greatest challenge, took place on the day that the Gates Cambridge Class of 2021 was officially announced. The panel was introduced and hosted by Professor Stephen […]

Class of 2021 announced

The Gates Cambridge Class of 2021 made up of 74 outstanding new scholars has been officially announced. The Gates Cambridge scholarship programme, which this year celebrates its 20th anniversary, is the University of Cambridge’s leading international postgraduate scholarship programme. It was established through a US$210 million donation to the University of Cambridge from the Bill […]

Serotonin and its role in emotional responses

Two new studies which shed light on the role of serotonin in emotional responses have been published in leading journals. Jonathan Kanen [2015] is lead author of both. The first is published in Translational Psychiatry and looked at the influence of the neurotransmitter serotonin on emotional reactions to social conflict. The study involved volunteers drawing […]

Scholar wins NASA Fellowship

A Gates Cambridge Scholar has won a prestigious NASA Fellowship to continue his studies on exoplanets. Luis Welbanks has been awarded a NASA Hubble Fellowship and will begin his programme in the autumn at Arizona State University. The Fellowship programme “enables outstanding postdoctoral scientists to pursue independent research in any area of NASA Astrophysics, using […]